Who
Steven B. Ketchum
EVP, Chief Scientific Officer
Company insider
Files Form 4 as: EVP, Chief Scientific Officer, Amarin Corporation; Sr. Vice President, R & D, Sunesis Pharmaceuticals.
In numbers
- Trades disclosed
- 465
- Buys
- 1
- Sells
- 24
- Bought
- $67K
- Sold
- $25.0M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 30 Jun 2008
- Last trade
- 1 Jul 2026
- Last filed
- 15 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jul 2026filed 15 Jul 2026 | AMRN Amarin CorporationBiotechnology | SEC FORM 4 Code M | —3,688 | filing |
| 1 Jul 2026filed 15 Jul 2026 | AMRN Amarin CorporationBiotechnology | SEC FORM 4 Code F | $30K1,887 at $15.94 | filing |
| 1 Jul 2026filed 15 Jul 2026 | AMRN Amarin Corporationoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,688 at $0.00 | filing |
| 1 Jul 2026filed 15 Jul 2026 | AMRN Amarin Corporationoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,688 at $0.00 | filing |
| 1 Jul 2026filed 15 Jul 2026 | AMRN Amarin CorporationBiotechnology | SEC FORM 4 Code M | —3,688 | filing |
| 1 Jul 2026filed 15 Jul 2026 | AMRN Amarin CorporationBiotechnology | SEC FORM 4 Code F | $30K1,887 at $15.94 | filing |
| 1 Feb 2026filed 3 Feb 2026 | AMRN Amarin Corporationoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,013 at $0.00 | filing |
| 1 Feb 2026filed 3 Feb 2026 | AMRN Amarin Corporationoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,060 at $0.00 | filing |
| 1 Feb 2026filed 3 Feb 2026 | AMRN Amarin Corporationoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,013 at $0.00 | filing |
| 1 Feb 2026filed 3 Feb 2026 | AMRN Amarin Corporationoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,060 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AMRN Amarin CorporationBiotechnology | SEC FORM 4 Code M | —2,246 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AMRN Amarin CorporationBiotechnology | SEC FORM 4 Code F | $19K1,235 at $15.42 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AMRN Amarin CorporationBiotechnology | SEC FORM 4 Code M | —1,933 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AMRN Amarin Corporationoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,246 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AMRN Amarin Corporationoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,933 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AMRN Amarin CorporationBiotechnology | SEC FORM 4 Code F | $16K1,062 at $15.42 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AMRN Amarin Corporationoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,246 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AMRN Amarin Corporationoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,933 at $0.00 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AMRN Amarin CorporationBiotechnology | SEC FORM 4 Code M | —2,246 | filing |
| 31 Jan 2026filed 3 Feb 2026 | AMRN Amarin CorporationBiotechnology | SEC FORM 4 Code F | $19K1,235 at $15.42 | filing |
News
Amarin (NASDAQ:AMRN) and Merck KGaA (OTCMKTS:MKKGY) Financial ReviewAMRN · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name Steven B. Ketchum; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.